Pathophysiology and therapeutic potential of cardiac fibrosis

Table 1 Clinical trials using cardiac stem cells

Trial			CADUCEUS	SCIPIO
Inclusion criteria	Patient characteristics		Previous MI	Previous MI and CABG
Inclusion criteria	EF (%)		25–45	≤40
No. of patients	Total		25	23
	Cell therapy group		17	16
	Control group		8	7
Cell therapy	Type of cardiac stem cells		Cardiosphere-derived cells	c-kit-positive CPCs
	Dose of injected cells		12.5–25 million	0.5–1 million
	Delivery method		Intracoronary infusion	Intracoronary infusion
	Timing of delivery		1.5–3 months after MI	4 ± 1 months after CABG
Outcomes	EF (%); baseline/follow-up	Cell therapy	42.4/48.2 (1 year)	30.3/38.5 (4 months)
	EF (%); baseline/follow-up	Control	42.5/48.1 (1 year)	30.1/30.2 (4 months)
	Scar size (%LV or g); baseline/follow-up	Cell therapy	23.8/12.9 (1 year) (%LV)	32.6/22.8 (1 year) (g)
	Scar size (%LV or g); baseline/follow-up	Control	22.4/20.3 (1 year) (%LV)	N/A
References			[51, 52]	[53]

CABG coronary artery bypass grafting;, CPCs cardiac progenitor cells, EF ejection fraction, LV left ventricular, MI myocardial infarction, N/A not available

ISSN: 1880-8190